Abstract

A QUALITATIVE ANALYTICAL RESEARCH ON THE MOLECULAR PHARMACOLOGY OF GEMIGLIPTIN

Dr. Moumita Hazra*1, 2, 3, 4, 5

ABSTRACT

Introduction: In accordance with the guidelines of diabetes associations, gemigliptin-like anti-dipeptidyl peptidase-4 (DPP-4) hypoglycaemic drugs, are being quite extensively used as one of the effective anti-diabetic therapeutic agents, which cause augmented beta-cell function by ameliorating the anti-beta cell apoptotic serum incretins, such as, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibitors are the most prevailing incretin-related therapies for T2D diabetics. Objectives: The objective of this study was to conduct a qualitative analytical research on the molecular pharmacology of gemigliptin. Methods: In this study, a qualitative molecular pharmaco-analysis of gemigliptin was conducted. Results: The molecular pharmaco-analysis showed a well-structured and functional synchrony of gemigliptin, with clinical pharmacological pleiotropism. Conclusions: Gemigliptin had shown remarkable molecular efficacy, with functional pleiotropism.

Keywords: Gemigliptin, Dipeptidyl peptidase-4 inhibitors, Molecular Pharmacology, Analytical Research.